ANTX — AN2 Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $36.72m
- -$46.90m
- 18
- 50
- 76
- 46
Annual cashflow statement for AN2 Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.6 | -21.5 | -41 | -64.7 | -51.3 |
| Non-Cash Items | 7.01 | 1.03 | 3.78 | 5.61 | 5.06 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.22 | 0.032 | 3.72 | 5.83 | -3 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -5.36 | -20.5 | -33.5 | -53.3 | -49.3 |
| Other Investing Cash Flow Items | 0 | -50 | -21.8 | -43.3 | 54.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -50 | -21.8 | -43.3 | 54.6 |
| Financing Cash Flow Items | 0 | -1.21 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 3.84 | 78.5 | 70.4 | 85 | 0.372 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.53 | 8.03 | 15.1 | -11.6 | 5.7 |